&lt;p&gt;Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib&lt;/p&gt;

Lü, Shun

doi:10.2147/ott.s188296

Cited by 4 publications

(3 citation statements)

References 84 publications

(244 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, SCC patients tend to be older than those with AC [ 22 ]. Ultimately, the prognosis for gerontal patients with advanced NSCLC is poorer for those with SCC than for those with AC [ 6 , 23 ]. Therefore, it is necessary to construct a model to assess the prognosis for elderly SCC patients, to assist clinicians in making therapeutic strategies for these patients.…”

Section: Discussionmentioning

confidence: 99%

A prognostic model for elderly patients with squamous non-small cell lung cancer: a population-based study

Chen

Gao

et al. 2020

J Transl Med

View full text Add to dashboard Cite

Background Squamous cell carcinoma (SCC) is a main pathological type of non-small cell lung cancer. It is common among elderly patients with poor prognosis. We aimed to establish an accurate nomogram to predict survival for elderly patients (≥ 60 years old) with SCC based on the Surveillance, Epidemiology, and End Results (SEER) database. Methods The gerontal patients diagnosed with SCC from 2010 to 2015 were collected from the Surveillance, Epidemiology, and End Results (SEER) database. The independent prognostic factors were identified using multivariate Cox proportional hazards regression analysis, which were utilized to conduct a nomogram for predicting survival. The novel nomogram was evaluated by Concordance index (C-index), calibration curves, net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). Results 32,474 elderly SCC patients were included in the analysis, who were randomly assigned to training cohort (n = 22,732) and validation cohort (n = 9742). The following factors were contained in the final prognostic model: age, sex, race, marital status, tumor site, AJCC stage, surgery, radiation and chemotherapy. Compared to AJCC stage, the novel nomogram exhibited better performance: C-index (training group: 0.789 vs. 0.730, validation group: 0.791 vs. 0.733), the areas under the receiver operating characteristic curve of the training set (1-year AUC: 0.846 vs. 0.791, 3-year AUC: 0.860 vs. 0.801, 5-year AUC: 0.859 vs. 0.794) and the validation set (1-year AUC: 0.846 vs. 0.793, 3-year AUC: 0.863 vs. 0.806, 5-year AUC: 0.866 vs. 0.801), and the 1-, 3- and 5-year calibration plots. Additionally, the NRI and IDI and 1-, 3- and 5-year DCA curves all confirmed that the nomogram was a great prognosis tool. Conclusions We constructed a novel nomogram that could be practical and helpful for precise evaluation of elderly SCC patient prognosis, thus helping clinicians in determining the appropriate therapy strategies for individual SCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A prognostic model for elderly patients with squamous non-small cell lung cancer: a population-based study

Chen

Gao

et al. 2020

J Transl Med

View full text Add to dashboard Cite

show abstract

“…Non-small cell lung cancer (NSCLC) accounts for the majority (>85%) of all lung cancers, including lung adenocarcinoma, lung squamous cell carcinoma (LUSC), and large cell lung cancer (3,4). Among them, LUSC is strongly associated with smoking (3), and about 30% of NSCLC patients in China have LUSC histology, similar to that of the United States (5). However, the actual patient number is higher due to the proportionality of the larger Chinese population.…”

Section: Introductionmentioning

confidence: 99%

LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY

Zhang

Sun

et al. 2019

Cancer Research

View full text Add to dashboard Cite

Somatic long interspersed element-1 (LINE-1) retrotransposition is a genomic process that relates to gene disruption and tumor occurrence. However, the expression and function of LINE-1 retrotransposition in lung squamous cell carcinoma (LUSC) remain unclear. We analyzed the transcriptomes of LUSC samples in The Cancer Genome Atlas and observed LINE-1 retrotransposition in 90% of tumor samples. Thirteen LINE-1 retrotranspositions of high occurrence were identified and further validated from an independent Chinese LUSC cohort. Among them, LINE-1-FGGY (L1-FGGY) was identified as the most frequent LINE-1 retrotransposition in the Chinese cohort and significantly correlated with poor clinical outcome. L1-FGGY occurred with smoke-induced hypomethylation of the LINE-1 promoter and contributed to the development of local immune evasion and dysfunctional metabolism. Over-expression of L1-FGGY or knockdown of FGGY promoted cell proliferation and invasion in vitro, facilitated tumorigenesis in vivo, and dysregulated cell energy metabolism and cytokine/ chemotaxin transcription. Importantly, specific reverse transcription inhibitors, nevirapine and efavirenz, dramatically countered L1-FGGY abundance, inhibited tumor growth, recovered metabolism dysfunction, and improved the local immune evasion. In conclusion, hypomethylation-induced L1-FGGY expression is a frequent genomic event that promotes the development and progression of LUSC and represents a promising predictive biomarker and therapeutic target in LUSC. Significance: LINE-1-FGGY is a prognosis predictive biomarker and potential therapeutic target to overcome local immune evasion in lung squamous cell carcinoma.

show abstract

“…Although these mutations are more common in ADCs, they do appear in SQC as well, but at a lower rate (3.3% in Western and 4.6% in Asian populations). The aforementioned EGFR mutations are predictive for their response to drugs called tyrosine kinase inhibitors (TKIs) that bind to tyrosine kinase receptors, reversibly or irreversibly, and inhibit downstream signaling [63]. To date, the US Food and Drug Administration (FDA) has approved five TKIs for the treatment of NSCLC.…”

Section: Predictive Biomarkers For Targeted Therapy In Nsclc Patientsmentioning

confidence: 99%

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

Šutić

Vukić

Baranašić

et al. 2021

JPM

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the “one-fits-all” paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer.

show abstract

<p>Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib</p>

Cited by 4 publications

References 84 publications

A prognostic model for elderly patients with squamous non-small cell lung cancer: a population-based study

A prognostic model for elderly patients with squamous non-small cell lung cancer: a population-based study

LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

Contact Info

Product

Resources

About